rider13 schreef op 27 februari 2018 10:07:
OGI (TSX)
Summary
OrganiGram delivered promising Q1 results, thanks to its oil sales.
The company is well-positioned to become the top player in the medical cannabis space by 2021.
OrganiGram is undervalued and has a 50% upside from the closing price on February 16.
Investment thesis